News | December 30, 2025
Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Now a test that offers new precision in prostate cancer detection
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Subscribe To Our Newsletter & Stay Updated
